key: cord-0272310-ikvz85no authors: Rothen, Dominik A.; Krenger, Pascal S.; Nonic, Aleksandra; Balke, Ina; Vogt, Anne-Cathrine S.; Chang, Xinyue; Manenti, Alessandro; Vedovi, Fabio; Resevica, Gunta; Walton, Senta M.; Zeltins, Andris; Montomoli, Emanuele; Vogel, Monique; Bachmann, Martin F.; Mohsen, Mona O. title: Intranasal administration of a VLP-based vaccine against COVID-19 induces neutralizing antibodies against SARS-CoV-2 and Variants of Concerns date: 2021-09-10 journal: bioRxiv DOI: 10.1101/2021.09.10.459749 sha: 6c2a4f08138e622a76d45e60d90ffde12b7ce7ef doc_id: 272310 cord_uid: ikvz85no Background The highly contagious SARS-CoV-2 is mainly transmitted by respiratory droplets and aerosols. Consequently, people are required to wear masks and maintain a social distance to avoid spreading of the virus. Despite the success of the commercially available vaccines, the virus is still uncontained globally. Given the tropism of SARS-CoV-2, a mucosal immune reaction would help to reduce viral shedding and transmission locally. Only seven out of hundreds of ongoing clinical trials are testing the intranasal delivery of COVID-19 vaccines. Methods In the current study, we tested in murine model the immunogenicity of a conventional vaccine platform based on virus-like particles (VLPs) displaying RBD of SARS-CoV-2 for intranasal vaccination. The candidate vaccine, CuMVTT-RBD, has been immunologically optimized to incorporate tetanus-toxin and is self-adjuvanted with TLR7/8 ligands. Results CuMVTT-RBD elicited strong RBD- and spike- specific systemic IgG and IgA antibody responses of high avidity. Local immune responses were assessed and results demonstrate strong mucosal antibody and plasma cell production in lung tissue. The induced systemic antibodies could efficiently recognize and neutralize different Variants of Concerns of mutated SARS-CoV-2 RBDs. Conclusion In summary, intranasal vaccination with CuMVTT-RBD shows high immunogenicity and induces protective systemic and local specific antibody response against SARS-CoV-2 and its variants. One sentence summary Evaluation of an intransal administrated conventional VLP-based vaccine against COVID-19 in a murine model. In order to generate a vaccine-candidate against SARS-CoV-2 for i.n. administration, we have 99 utilized our optimized plant-derived VLPs (CuMVTT-VLPs) as a vaccine platform 19, 15 . RBD 100 amino acid sequence (a.a. Arg319-Phe541) of SARS-CoV-2 was chemically coupled to 101 CuMVTT-VLPs using SMPH bifunctional cross-linker (Fig. 1a) . The generated vaccine 102 candidate CuMVTT-RBD is self-adjuvated with prokaryotic ssRNA (TLR7/8 agonist) which is 103 packaged during expression and assembly in the bacterial E. coli system (Fig. 1b) . Efficiency 104 of RBD coupling to CuMVTT-VLPs was confirmed by SDS-PAGE (Fig. 1c) . The integrity of the 105 VLPs following the coupling process was checked by electron microscopy and showed no 106 signs of aggregation (Fig. 1d) . The avidity of an Ab is defined as the binding strength through points of interaction. It 120 can be quantified as the ratio of Kd for the intrinsic affinity over the one for functional affinity of 121 a single point interaction 19 . High avidity Abs are formed upon affinity maturation in germinal 122 centers (GCs) and are associated with protective immunity against SARS-CoV-2 infection 20 . To assess the avidity of the induced IgG Abs against RBD, we carried out an avidity ELISA 124 using day 49 sera. The obtained results indicated that about 40% of the systemically induced 125 RBD-specific IgGs are of high avidity following the i.n. vaccination (Fig. 2 f and g) . and IgG2b being the dominant ones. In contrast, no IgG subclasses were detected in the 135 control group (Fig. 3a) . The vaccine was also able to induce isotype switching to IgA as shown 136 in Fig. 3b . Approximately, 20% of serum IgA Abs were of high avidity as shown in (Fig. 3c-d) . specific IgG levels were slightly lower (Fig 4) . However, the difference observed between RBD 144 VOCs and RBDwt IgG levels were statistically not significant (p=0.28). These findings indicate 145 a broad potential protective capacity of Abs induced by i.n. vaccination with CuMVTT-RBD. To test the ability of the CuMVTT-RBD vaccine to induce a humoral immune response in the 149 lung mucosa; BAL was collected two weeks after the booster injection (day 42) and assessed 150 for RBD and spike protein specific IgG and IgA ( Fig. 5a-f ). RBD-and spike-specific IgG Abs 151 were detected at equal levels in the BAL (Fig. 5a-c) . However, IgA Abs in BAL were more 152 abundant against RBD than against spike protein ( Fig. 5d-f ). We have also assessed the 153 induced RBD-specific IgG subclasses in BAL. Interestingly, the local mucosal IgG response 154 was less balanced than the serum response and dominated by IgG2b (Fig. 5g ). Next, we tested To test the ability of the sera of immunized mice to inhibit binding of RBD to ACE2, a biolayer 174 interferometry competition assay was performed. Accordingly, RBD was immobilised onto anti- His biosensors and binding capacity of ACE2 to RBD in the presence of serum samples was 176 quantified. As depicted in Figure 7a , the binding of ACE2 to RBD was reduced in the presence 177 of sera from CuMVTT-RBD vaccinated mice. In contrast, no binding inhibition was observed in To assess the subclass Ab response, the same procedure was performed. The To test the avidity of IgG and IgA Ab against RBD, the above-described protocol was expanded 349 by an additional step. Following serum incubation at RT for 1h, the plates were washed once 350 in PBS/0.01% Tween, and then washed 3x with 7M urea in PBS-0.05%Tween or with PBS- COVID-19 vaccines that reduce symptoms but do not block infection need 443 higher coverage and faster rollout to achieve population impact Clinical progression and viral load in a community outbreak Atlas of ACE2 gene expression reveals novel insights into 447 transmission of SARS-CoV-2 ACE2 Receptor Expression and Severe Acute Respiratory Syndrome 449 Coronavirus Infection Depend on Differentiation of Human Airway Epithelia Mechanisms of SARS-CoV-2 Transmission and 452 SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues SARS-CoV-2 vaccines in development Role of IgA versus Control of Influenza Viral Infection in the Murine Respiratory Tract Role of IgA in the defense against respiratory infections: IgA deficient mice 462 exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG The establishment of resident memory B cells in the lung requires local 465 antigen encounter Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces 467 shedding of SARS-CoV-2 D614G in rhesus macaques Immune responses after live attenuated 470 influenza vaccination Efficient induction of mucosal and systemic immune responses by virus-like 472 particles administered intranasally: Implications for vaccine design Incorporation of tetanus-epitope into virus-like particles achieves vaccine 475 responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based 480 colorimetric live virus micro-neutralization assay in human serum samples The theory and practice of the viral dose in neutralization assay: Insights on 483 SARS-CoV-2 'doublethink' effect The 3Ds in virus-like particle based-vaccines: 485 "Design, Delivery and Dynamics The potential significance of high avidity immunoglobulin G (IgG) for protective 487 immunity towards SARS-CoV-2 Murine IgG1 complexes trigger immune effector functions predominantly 489 via Fc gamma RIII (CD16) BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-491 reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced Mucosal Immunity in COVID-19: A 494 Neglected but Critical Aspect of SARS-CoV-2 Infection Mucosal Delivery Routes for Optimal Immunization: Targeting Immunity to the 496 Right Tissues Major findings and recent 498 advances in virus-like particle (VLP)-based vaccines RNA and toll-like receptor 7 license the generation of superior secondary 500 plasma cells at multiple levels in a B cell intrinsic fashion Alveolar Macrophages and Lung Dendritic Cells Sense RNA and Drive Mucosal 502 IgA Responses Development of a vaccine against sars-cov-2 based on the receptor-binding 504 domain displayed on virus-like particles Enhanced SARS-CoV-2 neutralization by dimeric IgA IgA subclasses have different effector functions associated with distinct 508 glycosylation profiles Fc receptor-targeted mucosal vaccination 510 as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal 511 pathogens Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting Molecular definition of severe acute respiratory syndrome coronavirus 2 515 receptor-binding domain mutations: Receptor affinity versus neutralization of receptor 516 interaction SARS-CoV-2 structural 518 features may explain limited neutralizing-antibody responses The trinity of COVID-19: 520 immunity, inflammation and intervention Resident memory CD8+ T cells in the upper respiratory tract prevent 522 pulmonary influenza virus infection Enhanced Neutralizing Antibody Titers and Th1 Polarization from a 524 Novel Escherichia coli Derived Pandemic Influenza Vaccine